Get started
Author

Natty Chalermpalanupap

Observed institution: AbbVie (United States)
OpenAlex ID: A5069196967
Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
2024 · Jessica Ailani, Pranav Gandhi, et al. · Headache The Journal of Head and Face Pain · 6
PDF
Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
2024 · Richard B. Lipton, Stephanie J. Nahas, et al. · The Journal of Headache and Pain · 6
Change in Migraine Based on a Patient Global Impression of Change in Participants with Episodic Migraine and Chronic Migraine: Results from 5 Atogepant Clinical Trials (P8-12.006)
2024 · Peter Goadsby, Pranav Gandhi, et al. · Neurology · 1
Impact of Atogepant on Functional Outcomes in Trial Completers for the Preventive Treatment of Episodic Migraine: A Post-Hoc Analysis of the ADVANCE Trial (S35.003)
2025 · Andrew Blumenfeld, Pranav Gandhi, et al. · Neurology
Impact of Atogepant on Migraine Headache Severity for the Preventive Treatment of Episodic Migraine: A Post-Hoc Analysis of the 12-Week ADVANCE and 52-Week Open-Label Trials (P9-12.003)
2025 · Umer Najib, Belinda Savage-Edwards, et al. · Neurology
Episodic migraine with prior treatment failure: post hoc analysis of the ELEVATE trial
2024 · Simona Sacco, Krisztian Nagy, et al.
Benefit-risk assesment of atogepant: A post hoc anlysis of the advance trial
2023 · Stephanie Nahas, Jessica Ailani, et al. · Journal of the Neurological Sciences
PDF
Benefit-Risk Assessment of Atogepant: A Post Hoc Analysis of the ADVANCE Trial (P12-12.001)
2023 · Stephanie Nahas, Jessica Ailani, et al. · Neurology
Works count: 8
Citation count: 13
H-index: 2
I10-index:
Year
Topic
Type